查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493199

日本CDMO（合约药物开发和製造组织）市场规模、份额、趋势分析报告：按产品类型、工作流程、应用、国家、细分市场预测，2024-2030年

Japan Contract Development Manufacturing Organization Market Size, Share & Trends Analysis Report By Product Type, By Workflow, By Application, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 127 Pages | 商品交期: 2-10个工作天内

价格

日本CDMO市场成长及趋势：

Grand View Research, Inc.最新报告显示，预计到2030年日本CDMO市场规模将达到194.9亿美元，2024年至2030年复合年增长率为6.8%。

生物製药需求的增加、疾病负担的增加以及老年人口的增加是一些关键的成长要素。各种合约药物开发和受託製造厂商（CDMO）对设施和服务扩展的投资不断增加，可能会在预测期内提振市场。

此外，製药公司增加研发投资正在推动市场成长。随着製药公司增加研发投资，他们可能会寻求外部专业知识和资源来加速药物开发进程。 CDMO 为药物开发、製造和测试提供专业服务，使其成为寻求委託其研发活动某些方面的製药公司的宝贵合作伙伴。多家公司正在投资药品研发活动。例如，2022年3月，药明康德宣布推出四环霉素相容的自惰性腺病毒（TESSA）技术，以加速用于细胞和基因治疗药物的腺结合病毒的生产。

製药公司外包服务的增加对日本市场产生了重大影响。随着公司看到成功的药物开发和商业化所必需的付加能力的价值，製药领域外包活动的趋势正在增加。除了提供专业知识和改善现金流管理之外，外包还提供显着的製造优势，例如降低投资风险。

值得注意的是，日本监管机构正在加速再生医学和基因治疗产品的核准。例如，《药品和医疗设备法案》（PMD法案）、《21世纪治癒法案》和PRIME（优先药物）倡议的通过帮助日本改善了再生医学的可及性。监管机构的此类倡议预计将改善该国再生医学开发和製造的需求。

日本 CDMO 市场报告亮点

  • 原料药(API) 领域在 2023 年占据市场主导地位，份额为 81.2%。该行业的成长是由竞争性药物开发和端到端合约开发和受託製造厂商(CDMO) 服务不断增长的需求所推动的。此外，原料药製造的进步、生物製药领域的成长以及老年人口的增加也是支持该领域成长的关键因素。
  • 这是由于对生物相似药、学名药和再生疗法等药品的强劲需求。商务用CDMO 可以透过提供知识、节省时间和提高成本效益来帮助解决这些情况。
  • 从应用来看，肿瘤领域在2023年将占据35.3%的销售份额，在检测类型市场中占据主导地位。再生医学产品和用于癌症治疗的病毒疗法的核准将进一步推动市场成长，而全球癌症患者数量的增加将进一步推动这一领域的发展。此外，药品研发投资的增加、专利到期以及对癌症治疗和生物创新的需求是推动肿瘤学领域成长的因素。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 日本 CDMO 市场的变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 日本CDMO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 日本CDMO市场：产品预估与趋势分析

  • 定义和范围
  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 日本CDMO市场波动分析
  • 2018年至2030年日本CDMO市场规模及趋势分析（依产品）
  • API
  • 药品

第五章 日本CDMO市场：工作流程估算与趋势分析

  • 定义和范围
  • 细分仪表板
  • 日本CDMO市场波动分析
  • 2018-2030 年日本 CDMO 市场规模与趋势分析（依工作流程）
  • 临床
  • 商业的

第六章 日本CDMO市场：应用预估与趋势分析

  • 定义和范围
  • 细分仪表板
  • 日本CDMO市场波动分析
  • 2018-2030 年日本 CDMO 市场规模及趋势分析（按应用）
  • 肿瘤学
  • 感染疾病
  • 神经病变
  • 循环系统疾病
  • 代谢紊乱
  • 自体免疫疾病
  • 眼科
  • 胃肠道疾病
  • 荷尔蒙失调
  • 血液疾病
  • 其他的

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 市场参与企业分类
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Lonza
    • Thermo Fisher Scientific, Inc.
    • Recipharm AB
    • Laboratory Corporation of America Holdings (LabCorp)
    • Catalent, Inc.
    • WuXi AppTec, Inc.
    • Samsung Biologics
    • CordenPharma International
    • Cambrex Corporation
    • Bushu Pharmaceuticals Ltd.
    • CMIC HOLDINGS Co., LTD.
    • Nipro Corporation
    • Sumitomo Chemical Company, Limited
Product Code: GVR-4-68039-985-5

Japan CDMO Market Growth & Trends:

The Japan CDMO market is expected to reach USD 19.49 billion by 2030 and is projected to register a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.

In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.

The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market.The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.

Japan CDMO Market Report Highlights:

  • The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.2% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
  • Based on workflow, the commercial segment held the largest market share in 2023, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
  • Based on application, the oncology segment dominated the test type market in 2023 with a revenue share of 35.3%, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Work Flow Type
    • 1.2.3. Application
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Type
    • 2.2.2. Work Flow Type
    • 2.2.3. Application
  • 2.3. Competitive Insights

Chapter 3. Japan CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing demand for Biopharmaceutical drugs in Japan
      • 3.2.1.2. High geriatric population and growing disease burden in Japan
      • 3.2.1.3. Low cost associated with Outsourcing Drug Manufacturing and Development services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited outsourcing opted by big pharma companies
      • 3.2.2.2. Quality Issues While Outsourcing
  • 3.3. Japan CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Japan CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. API
    • 4.1.2. Drug Product
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Japan CDMO Market Movement Analysis
  • 4.5. Japan CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
    • 4.5.1. API
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2. Type
      • 4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.4. Antibody Drug Conjugate (ADC)
      • 4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.5. Others
      • 4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3. Synthesis
      • 4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2. Synthetic
      • 4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2.2. Solid
      • 4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2.3. Liquid
      • 4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.3. Biotech
      • 4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4. Drug
      • 4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4.2. Innovative
      • 4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4.3. Generics
      • 4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.5. Manufacturing
      • 4.5.1.5.1. Continuous manufacturing
      • 4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.5.2. Batch manufacturing
      • 4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Drug Product
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.2. Oral solid dose
      • 4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.3. Semi-solid dose
      • 4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.4. Liquid dose
      • 4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.5. Others
      • 4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Japan CDMO Market: Workflow Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Clinical
    • 5.1.2. Commercial
  • 5.2. Segment Dashboard
  • 5.3. Japan CDMO Market Movement Analysis
  • 5.4. Japan CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
    • 5.4.1. Clinical
      • 5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.4.2. Commercial
      • 5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Japan CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Biologics
    • 6.1.2. Infectious Diseases
    • 6.1.3. Neurological Disorders
    • 6.1.4. Cardiovascular Diseases
    • 6.1.5. Metabolic Disorders
    • 6.1.6. Autoimmune Diseases
    • 6.1.7. Respiratory Diseases
    • 6.1.8. Ophthalmology
    • 6.1.9. Gastrointestinal Disorders
    • 6.1.10. Hormonal Disorders
    • 6.1.11. Hematological Disorders
    • 6.1.12. Others
  • 6.2. Segment Dashboard
  • 6.3. Japan CDMO Market Movement Analysis
  • 6.4. Japan CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and forecast 2018 to 2030 (USD million)
      • 6.4.1.2. Small Molecule
      • 6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
      • 6.4.1.3. Biologics
      • 6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.3. Neurological Disorders
      • 6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.4. Cardiovascular Diseases
      • 6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.5. Metabolic Disorders
      • 6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.6. Autoimmune Diseases
      • 6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.7. Respiratory Diseases
      • 6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.8. Ophthalmology
      • 6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.9. Gastrointestinal Disorders
      • 6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.10. Hormonal Disorders
      • 6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.11. Hematological Disorders
      • 6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.12. Others
      • 6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
  • 7.4. Market Participant Categorization
    • 7.4.1. List of key distributors and channel partners
    • 7.4.2. Key customers
    • 7.4.3. Key company market share analysis, 2023
    • 7.4.4. Lonza
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Recipharm AB
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Laboratory Corporation of America Holdings (LabCorp)
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Catalent, Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. WuXi AppTec, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Samsung Biologics
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. CordenPharma International
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. Cambrex Corporation
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. Bushu Pharmaceuticals Ltd.
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. CMIC HOLDINGS Co., LTD.
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives
    • 7.4.15. Nipro Corporation
      • 7.4.15.1. Company overview
      • 7.4.15.2. Financial performance
      • 7.4.15.3. Product benchmarking
      • 7.4.15.4. Strategic initiatives
    • 7.4.16. Sumitomo Chemical Company, Limited
      • 7.4.16.1. Company overview
      • 7.4.16.2. Financial performance
      • 7.4.16.3. Product benchmarking
      • 7.4.16.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Japan CDMO Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 4 Japan CDMO Market, Work Flow Type, 2018 - 2030 (USD Million)
  • Table 5 Japan CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 6 ADC Approvals in Japan
  • Table 7 Financial performance
  • Table 8 Key company initiating service launches/upgrades
  • Table 9 Key companies initiating service launches/upgrades
  • Table 10 Key companies initiating partnerships
  • Table 11 Key companies initiating expansion
  • Table 12 Key companies initiating expansion

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Japan CDMO market snapshot, 2023 (in USD Million)
  • Fig. 10 Segment snapshot, 2023 & 2030 (USD Million)
  • Fig. 11 Workflow Segment snapshot, 2023 & 2030 (USD Million)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Market dynamics
  • Fig. 14 Risk associated with outsourcing services
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTEL Analysis
  • Fig. 17 Japan CDMO market Product outlook: Segment dashboard
  • Fig. 18 Japan CDMO market: Product movement analysis
  • Fig. 19 API market, 2018 - 2030 (USD Million)
  • Fig. 20 Traditional APIs market, 2018 - 2030 (USD Million)
  • Fig. 21 HP-API market, 2018 - 2030 (USD Million)
  • Fig. 22 Antibody drug conjugate market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
  • Fig. 25 Solid market, 2018 - 2030 (USD Million)
  • Fig. 26 Liquid market, 2018 - 2030 (USD Million)
  • Fig. 27 No. of Biosimilar approvals (2012-2021)
  • Fig. 28 Biotech market, 2018 - 2030 (USD Million)
  • Fig. 29 Innovative market, 2018 - 2030 (USD Million)
  • Fig. 30 Generics market, 2018 - 2030 (USD Million)
  • Fig. 31 Continuous manufacturing process of tablets
  • Fig. 32 Continuous manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 33 Batch manufacturing process
  • Fig. 34 Batch manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 35 Oral solid dose market, 2018 - 2030 (USD Million)
  • Fig. 36 Semi-solid dose market, 2018 - 2030 (USD Million)
  • Fig. 37 Liquid dose market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Japan CDMO market workflow outlook: Segment dashboard
  • Fig. 40 Japan CDMO market: Workflow movement analysis
  • Fig. 41 Japan clinical trial
  • Fig. 42 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 43 Commercial market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan CDMO market synthesis outlook: segment dashboard
  • Fig. 45 Japan CDMO market: synthesis movement analysis
  • Fig. 46 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 47 Hormonal market, 2018 - 2030 (USD Million)
  • Fig. 48 Glaucoma market, 2018 - 2030 (USD Million)
  • Fig. 49 Cardiovascular disease market, 2018 - 2030 (USD Million)
  • Fig. 50 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Heat map analysis
  • Fig. 54 Market participant categorization